Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer

Cancer

Volumn 116, Issue 7, 2010, Pages 1699-1708

  Garzotto, Mark ^a   Higano, Celestia S ^b   O'Brien, Catherine ^a   Rademacher, Brooks L S ^a   Janeba, Nicole ^a   Fazli, Ladan ^c   Lange, Paul H ^b   Lieberman, Stephen ^d   Beer, Tomasz M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d University of British Columbia ^*  (United States)

Author keywords

Chemotherapy before prostatectomy; Docetaxel; Mitoxantrone; Neoadjuvant chemotherapy; Prostate cancer

Indexed keywords

BIOLOGICAL MARKER; DOCETAXEL; MITOXANTRONE; PROSTATE SPECIFIC ANTIGEN; VASCULOTROPIN;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CELLULITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAPHORESIS; DIARRHEA; DRUG DOSE ESCALATION; EPISTAXIS; EXTRAPYRAMIDAL SYNDROME; FATIGUE; FEBRILE NEUTROPENIA; FOLLOW UP; GASTROINTESTINAL REFLUX; HEARING LOSS; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPERPHOSPHATEMIA; HYPOPHOSPHATEMIA; INDIGESTION; INJECTION SITE REACTION; LACRIMATION DISORDER; LEUKOPENIA; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROPATHY; NEUTROPENIA; NIGHT SWEAT; ONYCHOLYSIS; PAIN; PARONYCHIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; TASTE DISORDER; THROMBOCYTOPENIA; THROMBOSIS; TISSUE MICROARRAY; URINARY TRACT INFECTION; VISUAL DISORDER; VOMITING; WEIGHT REDUCTION;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; HUMANS; MALE; MIDDLE AGED; MITOXANTRONE; NEOADJUVANT THERAPY; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECURRENCE; RISK; TAXOIDS; TESTOSTERONE;

EID: 77950295399     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24960     Document Type: Article

References (27)

1. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am. 2001;28:555-565.
2. Kuban DA, Thames HD, Levy LB, et al. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys. 2003;57:915-928.
3. D'Amico AV, Whittington R, Malkowicz SB, et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol. 1999;17:168-172.
4. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998;90:766-771.
5. Han M, Pound CR, Potter SR, Partin AW, Epstein JI, Walsh PC. Isolated local recurrence is rare after radical prostatectomy in men with Gleason 7 prostate cancer and positive surgical margins: therapeutic implications. J Urol. 2001;165:864-866.
6. Stephenson AJ, Shariat SF, Zelefsky MJ, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA. 2004;291:1325-1332.
7. Aus G, Abrahamsson PA, Ahlgren G, et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int. 2002;90:561-566.
8. Hurtado-coll A, Goldenberg SL, Klotz L, Gleave ME. Preoperative neoadjuvant androgen withdrawal therapy in prostate cancer: the Canadian experience. Urology. 2002;60:45-51; discussion 51.
9. Soloway MS, Pareek K, Sharifi R, et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol. 2002;167:112-116.
10. Gleave ME, Goldenberg SL, Chin JL, et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol. 2001;166:500-506; discussion 506-507.
11. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-1520.
12. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512.
13. Gleave M, Kelly WK. High-risk localized prostate cancer: a case for early chemotherapy. J Clin Oncol. 2005;23:8186-8191.
14. Beer TM, Garzotto M, Lowe BA, et al. Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res. 2004;10:1306-1311.
15. Dreicer R, Magi-Galluzzi C, Zhou M, et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology. 2004;63:1138-1142.
16. Konety BR, Eastham JA, Reuter VE, et al. Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study. J Urol. 2004;171:709-713.
17. Oh WK, George DJ, Kaufman DS, et al. Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report. Semin Oncol. 2001;28:40-44.
18. Hussain M, Smith DC, El-Rayes BF, et al. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer. Urology. 2003;61:774-780.
19. Chi KN, Chin JL, Winquist E, Klotz L, Saad F, Gleave ME. Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol. 2008;180:565-570; discussion 570.
20. Michels J, Montemurro T, Murray N, Kollmannsberger C, Nguyen Chi K. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter? Cancer. 2006;106:1041-1046.
21. Lacy C, Armstrong L, Goldman M, Lance L. Drug Information Handbook. 10th ed. Cleveland, OH: LexiComp Inc; 2002.
22. Sonpavde G, Chi KN, Powles T, et al. Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. Cancer. 2007;110:2628-2639.
23. Vickers AJ, Bianco FJ, Serio AM, et al. The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst. 2007;99:1171-1177.
24. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433-439.
25. Hammerer P, Hubner D, Gonnermann D, Huland H. Perioperative and postoperative complications of pelvic lymphadenectomy and radical prostatectomy in 320 consecutive patients [in German]. Urologe A. 1995;34:334-342.
26. Lerner SE, Blute ML, Lieber MM, Zincke H. Morbidity of contemporary radical retropubic prostatectomy for localized prostate cancer. Oncology (Williston Park). 1995;9:379-382; discussion 382, 385-386, 389.
27. Tewari A, Srivasatava A, Menon M. A prospective comparison of radical retropubic and robot-assisted prostatectomy: experience in 1 institution. BJU Int. 2003;92:205-210.